AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call
AbbVie (NYSE: ABBV) will disclose its fourth-quarter 2022 financial results on February 9, 2023, prior to market opening. A live webcast of the earnings conference call is scheduled for 8 a.m. CT and can be accessed via AbbVie's Investor Relations website. An archived version will be available later on the same day. AbbVie aims to innovate in various therapeutic areas including immunology, oncology, neuroscience, eye care, virology, and gastroenterology.
- Upcoming earnings announcement may provide insights into revenue and growth metrics.
- Potential for positive market reactions based on financial performance expectations.
- None.
NORTH CHICAGO, Ill., Jan. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-to-host-fourth-quarter-2022-earnings-conference-call-301711231.html
SOURCE AbbVie
FAQ
When will AbbVie announce its fourth-quarter 2022 financial results?
What time is AbbVie's fourth-quarter earnings conference call?
How can I access AbbVie's fourth-quarter earnings call?
What is AbbVie's focus in terms of therapeutic areas?